Trial Profile

Safety and efficacy of avelumab plus carboplatin patients with metastatic castration resistant prostate cancer progressing after one line of chemotherapy and one novel androgen receptor axis inhibitor: A phase Ib study

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 01 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Oct 2022 Results assessing Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer published in the British Journal of Cancer
21 Sep 2021 Results presented at the 46th European Society for Medical Oncology Congress
02 Jul 2018 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com